Patients with a Japanese, Korean, Taiwanese, or Chinese ethnic background of each country/region

Patients aged ≥20 years on the date of informed consent

Patients with histologically confirmed diagnosis of one of the following:

* Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)

* Angioimmunoblastic T-cell Lymphoma (AITL)

* Anaplastic large cell lymphoma (ALCL), (ALK-positive/negative)

Relapsed or refractory patients with a treatment history of at least one regimen with antitumor agents for the above disease

Have at least 1 measurable lesion

Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

Patients with a life expectancy of at least 3 months as determined by the investigator

A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)